None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
advanced stage
None
None
None
None
None
None
None
None
None
None
None
None
None
advanced stage
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
advanced stage
None
None
None
chronic obstructive pulmonary disease	treatment	smokers	mortality	subjects	pulmonary hypertension	inflammation	cells	lung function	studies	development	diagnosis	tuberculosis	asthma	disease	therapy	exercise	patient	diagnosis	smoking	infection	pneumonia	use	cigarette smoke	response	spirometry	oxygen	death	acute exacerbations	oxidative stress	index	prevalence	lung cancer	pulmonary embolism	depression	epithelial cells	obstructive pulmonary disease	time	factors	failure	hypertension	pulmonary emphysema	women	bacteria	increase	biomarkers	function	effects	test	heart failure	role	pulmonary tuberculosis	surgery	lungs	hospitalization	lobe	decline	admission	care	progression	interstitial lung disease	rate	morbidity	follow-up	intubation	inhaled corticosteroids	echocardiography	sleep	inflammatory cells	bronchodilators	dynamic hyperinflation	lung disease	protein	complications	outcome	pneumothorax	pulmonary artery	status	pattern	lung transplant	expression	lymphocytes	reduction	transplantation	ratio	fluid	non-smokers	airspace enlargement	pain	acute	nocardiosis	significant increase	pathways	value	disability	level	measurement	non-invasive ventilation	pulmonary arteries	roflumilast-treated group	destruction	disease progression	interstitial pneumonia	jirovecii	proliferation	vital capacity	damage	features	fibroblasts	flow limitation	mutations	pulmonary nocardiosis	viruses	anemia	atelectasis	kinase	mediators	reproducibility	success	airway	effect	events	fatigue	frequency	glutathione	mesothelioma	differences	hour	hypercapnic respiratory failure	mechanisms	colonization	inflammatory mediators	recovery	breathing	endothelial microparticles	large airways	repair	support	6-minute walk distance	areas	assessment	cell death	hemodynamics	intervention	long-acting bronchodilators	mean age	microparticles	pulmonary vascular disease	research	tachycardia	active tuberculosis	acute pulmonary embolism	cor pulmonale	embolism	epithelium	obstructive sleep apnea	progression	thromboembolism	apoptotic cells	incidence	inflammatory markers	pulmonary diseases	respiratory acidosis	sympathetic activation	Tuberculosis	X-ray	deep vein thrombosis	detection	detection	diseases	monitoring	cause	chemotherapy	health	hospital admission	mRNA	mother	Non-invasive ventilation	alveolar regeneration	gradient	illness	investigation	natriuretic peptide	overlap syndrome group	pneumoniae	venous thrombosis	aeruginosa	alveoli	antibiotic treatment	circulation	decline	fragmentation	heart	immunity	inhibition	nitric oxide	pulmonary vasculature	software	all-cause mortality	anthracofibrosis	chronic lung disease	diuretics	smooth muscle cells	thrombus	tolerance	upregulation	cardiopulmonary bypass	chronic mucus hypersecretion	conditions	dysfunction	infliximab	kidney	laughter	metabolism	mild chronic obstructive pulmonary disease	normal limits	repeatability	repeatability	sensitivity	sepsis	Apoptosis	alveolar walls	blood flow	cardiac	clearance	clinicians	cysteine	exercise capacity index	health outcomes	inflammatory response	old pulmonary tuberculosis	participation	rescue medication use	several limitations	stenosis	thrombosis	total mortality	Pulmonary hypertension	design	headache	human lung	hypertrophy	long-acting β2-agonists	lung cancer mortality	molecular mechanisms	oxidase	phenotypes	stratification	stress response	Factors	Improvement	bacterial colonization	binding	decline	early diagnosis	endothelin-1	etiology	independent risk factor	long-acting muscarinic antagonists	non-symptomatic smokers	onset	parenchymal destruction	significant improvement	skeletal muscle	sputum neutrophils	structure	suspicion	systemic oxidative stress	telomere syndromes	therapeutic targets	tissue repair	trial	vascular changes	% reduction	Sarcoidosis	antibiotic use	asthma	bacterial pneumonia	bronchi	complications	delay	disease development	elastase-induced emphysema	endothelial nitric oxide synthase	falls	hyperresponsiveness	lung function impairment	lung structure	mechanics	mmol/L	morbidity	myocardial infarct	potentials	prostacyclin	pulmonary infection	respiratory insufficiency	right ventricular function	sites	sleep apnea	small-airway obstruction	tumor necrosis factor-alpha	variations	adverse events	allergic rhinitis	basic fibroblast growth factor	comorbid depression	empyema	environment	factors	free radicals	hyperoxia	immune responses	inflammatory gene expression	inpatient mortality	intermittent positive pressure ventilation	mucus accumulation	nitric oxide synthase	part	primary care physicians	relapse	renal failure	rhinovirus	severe mitral regurgitation	short-acting anticholinergics	significant morbidity	subsets	water	The pathogenesis	acrolein	airflow	alveolar wall cells	basement membrane	bone mineral density	bronchial bacterial colonization	carbon dioxide retention	chronic lung diseases	close monitoring	composition	counseling	desaturation	dopamine	expertise	global mortality	histone deacetylase activity	human alveolar macrophages	immunosuppression	increased morbidity	inflammatory parameters	irreversible airflow obstruction	latent TB	life expectancy	loci	lung diseases	mellitus	mesenchymal transition	overproduction	primary graft dysfunction	progenitor cells	progressive airflow limitation	proteinases	rapid decline	rapid decline	recent advances	receptor expression	respiratory impedance	secondary intubation	sleep-disordered breathing	smoking-induced emphysema	stimuli	surfactant proteins	total number	transesophageal echocardiography	tumor emboli	vascular abnormalities	vimentin-positive cells	α1-PI deficiency	Irreversible asthma	The measurement	This decrease	adenocarcinomas	adverse outcomes	air pollutants	alveolar attachments	anti-TB medications	anticholinergic therapy	bodies	brain	bronchial microbial patterns	bronchiolar epithelium	bronchoalveolar lavage fluids	bronchoaspiration	cardiovascular morbidity	cell apoptosis	clinical assessment	clinical deterioration	cloning	current smoking status	declines	epidemiology	epidemiology	function tests	genes	healthy nonsmokers	helium	hemoptoe	hepatotoxicity	high morbidity	hospital outcome	host defense	hyper-responsiveness	imbalance	injured cells	jirovecii pneumonia	large airway	lower-lobe interstitial fibrosis	lung adenocarcinomas	men	microbiology	mometasone	movement	muscle training	nitric oxide inhalation	osteomyelitis	overload	oxidative damage	point	prevalent comorbidities	progressive decline	pulmonary inflammation	rapid diagnosis	respiratory complications	right heart thrombi	skin	sputum	sputum inflammatory cells	static lung volumes	subpopulations	suicide attempt	survival	total cells	track layout	vaccination	vascular structure	vasculature	ventilation-perfusion relationships	ventricular filling	vessel	walk distance	6-minute-walk test	Another factor	Conditions	Japanese men	Prognosis	Serial changes	The lung tissue microbiome	The structure	accelerated decline	advantage	alveolar units	alveolitis	anatomy	antiapoptotic markers	antiviral treatment	arise	artery hypertension	autologous lung cells	bacteria	bacterial colonisation	beneficial effect	beta-adrenergic blockers	body composition	bronchial vessels	challenges	changes	chromatin remodeling	chronic airway infection	chronic inflammatory lung diseases	chronic lung inflammation	chronic mucus production	chronic obstructive airway disease	chronic respiratory infection	clinical conditions	control smokers	cough reflex	couples	deep venous thrombosis	delay	desmosine excretion	different points	emergency room visits	emphysema progression	endothelial function	environmental insults	epithelial cell apoptosis	epithelial cell viability	erythrocytes	examination	expiratory airflow limitation	factor-α gene promoter polymorphism	fracture	functional exercise capacity	fungi	gains	gelatinolytic activity	healthy ” smokers	heart thrombi	helium-oxygen	important factor	impulse oscillometry	indoor air quality	inhaled tiotropium	intracellular oxidative stress	intubation rates	kinase activities	lung cryobiopsy	lung markings	major risk factor	mass	mast cells	morphine	mucociliary transport	multi-functional molecule	muscle dysfunction	natural variation	neuroendocrine	new blood vessels	non-smokers	non-symptomatic smokers	oral prednisolone	outflow obstruction	oxidant burden	oxidative stress	pallor	particular concern	pathogenic mechanisms	pathological correlation	point	population-attributable risk	previous steroid	protease production	pulmonary gas exchange	ratios	receptor antagonists	respiratory muscle fatigue	resting	risk factor	secondary bacterial infection	serotonin transporter gene	severe asthma	significant reductions	skeletal muscle dysfunction	smoke-induced lung inflammation	smooth muscle hyperplasia	success	swelling	symptom score	synthase enzyme	systemic condition	systemic effects	undergoing apoptosis	useful tool	vascular progenitor cells	ventricular dimensions	weight gain	10.2147/COPD.S51226copd-9-1207ReviewOxidative stress	10.2147/COPD.S78677copd-10-2137ReviewLung transplantation	5-lipoxygenase activity	A common finding	A common practice	A delay	A leaky alveolar-capillary barrier	An important event	An integrated approach	Anxiety	Both hypoxia	Diagnostic procedures	EMP subtypes	ER-derived oxidative stress	Epithelial integrity	Epithelial-to-mesenchymal transition	Exertional dyspnea	MMP-12-mediated inflammation	Noninfectious factors	Pulmonary infection	Several advances	Some nonspecific symptoms	TH2-mediated sensitization	The acute improvement	The cellular profile	The chronic bronchitis phenotype	The cytokine network	The macrophage	The marked variability	The neutrophil	Timely diagnosis	Tobacco treatment	Vascular changes	abnormal alveolar development	abscess	absorption	accelerated decline	accelerated longitudinal decline	activated leukocytes	active form	acute interstitial syndromes	acute venous thrombosis	adaptor proteins	additional benefit	adenocarcinoma mutation profile	affect symptoms	age	al21	alveolar glutathione	alveolar remodeling	alveolar surfactant system	analyzed changes	and/or Western blot	and/or macrophages	and/or psychotherapy	antibody titers	anticholinergic use	antimicrobial therapy	antioxidant vitamin intake	anxiety	apoptotic events	arterial	arterial enlargement	artery measurements	assigns patient categorization	associated high morbidity	attendant risks	awesome morbidity	bacterial etiology	bacteriologic etiology	base excision repair genes	biventricular function	bone infection	bone resorption	bronchial epithelial cell senescence	bronchial etiologies	bronchial hypersecretion	bronchial microbiome	bronchial vasculature	bronchoalveolar lavage cytology	bronchodilator reversibility	c-fos transcription	cancer prevention	cardiac dysfunction predict mortality	cardiac hypertrophy	cardiac structure	cardiopulmonary responses	care utilization	carotid artery thickening	carriage	carriage	case detection	causative factor	cellular aerobic respiration	central parameter	central respiratory control	changes	choices	chronic bronchitis	chronic heart	chronic inflammatory responses	chronic interstitial inflammatory infiltrates	chronic obstructive lung diseases	chronic oxygen therapy	chronic pulmonary thromboembolism	chronic respiratory illnesses	ciliated epithelial cell numbers	clinical evaluation	clinical indices	clinical measurements	clinical procedures	clinical status	colony-forming capacity	combined morbidity	common finding	common subjects	comorbidity management	conception	concurrent anxiety	confounding features	considerable individual morbidity	considerable interest	corticosteroid efficacy	critical care utilization	crucial pathophysiological mechanisms	daily condition	decreased mortality	deficiency	deficits	delay	demonstrate benefit	described similar lymphoid follicles	detailed observation	deteriorations	difficult problem	difficulties	disease pathogenesis	disease results	disease-specific autoantibodies	dismutase	dissimilarity	distinct molecular pathway	drastic changes	early diagnosis	early manifestation	early morbidity	early therapeutic predictor	eicosanoids	either anticoagulation therapy	either nonsmokers	elastin fibers	elastinolysis	electrocardiographic gating	emphysema dominant	endogenous nitric oxide	endothelial maintenance	endurance capacity	epigenetics	epithelial cell-derived cathepsins	excess cost	exercise-induced oxidative stress	exercise-related oxygen desaturation	exercises	expiratory reactance	expression changes	factor-alpha overexpression	faster decline	fibroblast growth factor	first exacerbations	fivefold increase	fluid accumulation mechanisms	focal wheezes	frequent exacerbator phenotype	fumes5,6	gastro-esophageal reflux	glycoprotein	gold standard	growth factor-beta1	heparin sulfate	histopathologic changes	histopathologic changes	human epithelial cells	human health	human pulmonary artery	hypercoagulable state	idea	identifiable landmarks	ie improving symptoms	immediate/early protective gene	immune-mediated inflammation	immunity proteins	immunomodulatory activities	immunosuppressive therapy	important causative factor	important comorbidities	important etiological factor	improvements	inappropriate delay	increased age	independent factor	individual body mass index	induced hyperinflation	infant morbidity	inflammatory	inflammatory indices	inflammatory lung diseases	inflammatory pathways	inhalation compliance	inhaled matter	initiation	interleukin-6	interventions	intravenous glucocorticoids	irreversible pathological changes	ischemic heart diseases	isoenzyme	killer cells	known heart	known history	last attendance	late survival	leucocyte adhesion	lung alveolar cell apoptosis	lung densitometry	lung fibroblast cells	lymphoid neogenesis	mannose receptor	many different factors	marked expression	maximal expiratory efforts	metastases	mice results	microbial sources	mitochondrial gene expression	monocyte chemotaxis	months results	morphologic derangements	motility	much lower,55	mucosal biopsies	mucus-secreting glands	multiple mediators	multiple uses	myeloperoxidase inhibitors,95	neck stiffness	neoangiogenesis	neurology	neutrophil elastase gene	next exacerbation	nighttime awakenings	noncardiac complications	normal airways	normal growth	normal individuals	normal lung volumes	normal right ventricular size	normal size	nuclear periphery	number-one risk factor	numerical imbalance	nutritional status	once-daily aclidinium	ongoing oxidant burden	osteoblastic activity	osteoclastic proliferation	oxidized/nitrosylated proteins	palliative use	pancreatic edema	panlobular pulmonary emphysema	paracetamol exposure	parenchymal structure	particulate agents	pathophysiological condition	patient morbidity	patient response	pepsin	perioperative morbidity	peroxide exhalation	persistent exercise intolerance	physiological signaling	place	plaque formation	pleurapulmonary disease	polymorphism	poor nutritional status	positive chest X-ray	possible delay	possible prothrombotic activity	post-index change	postnasal drip syndrome	postoperative morbidity	potential protective role	potential risk	preexisting cardiac	premature mortality	prenatal diagnosis	primary human epithelial cells	pro-inflammatory stimuli	progressive respiratory failure	protease release	protective role	protein–MDA adducts	protracted course	psychological theory	psychotherapy	pulmonary aspergillosis	pulmonary cytokine expression	pulmonary distress	pulmonary hypoxia	pulmonary interstitial fibrosis	pulmonary vascular morphology	pulmonary vascular remodelling	rapid declines	rapid increase	recent decline	redox status	reduced exacerbations	reduced morbidity	refractory brain	regional drug deposition	rehospitalization	related phenotypes	relevant role	research questions	resected lung adenocarcinomas	respiratory rehabilitation	rhinovirus-infected airway epithelial cells	right chest pain	right ventricle enlargement	right ventricular size	right ventricular volume	risks	scan changes	selective pulmonary vasodilatation	self-reported gastroesophageal reflux disease	seropositivity	several etiologies	several important outcomes	severe lung dysfunction	severe restrictive pattern	short-acting anticholinergics	significant improvement	significant role	significant short-term morbidity	skeletal remodeling	small pulmonary artery	small-airway obstrcution	small-airway submucosa	smoke-induced endothelin receptor expression	smoke-induced pulmonary emphysema	smoking history	smoking-related morbidity	smooth muscle content	so-called susceptible smokers	specific immune responses	spirometric obstruction	stable angina	stagnation	stimulated tumor growth	structural diseases	subsequent improvements	substantial improvement	substantial variability	syncytial virus persistence	tidal flow-volume curves	tissue structure	tissue-specific difference	tobacco-smoke-induced emphysema	topics	total morbidity	tranbronchial cryobiopsy	treatment changes	troponins	tuberculosis incidence	turbulent flow	undergone lung volume reduction	undiagnosed airflow obstruction	unfolded protein response	used modality	usual presentation	utility	valuable tool	variables	varied incidence	various prong sizes	ventricular size	vessel remodelling	viruses	vs conventional glucocorticoid therapy	weigth loss	well-described nonspecific clinical manifestations	whole lung
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
